Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer.

Apoptosis BMP7 Cell survival Chemoresistance Chemotherapy Prss11

Journal

Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 22 03 2023
accepted: 05 03 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 12 4 2024
Statut: aheadofprint

Résumé

Chemotherapy drugs efficiently eradicate rapidly dividing differentiated cells by inducing cell death, but poorly target slowly dividing cells, including cancer stem cells and dormant cancer cells, in the later course of treatment. Prolonged exposure to chemotherapy results in a decrease in the proportion of apoptotic cells in the tumour mass. To investigate and characterize the molecular basis of this phenomenon, microarray-based expression analysis was performed to compare tHcred

Identifiants

DOI: 10.1007/s10585-024-10283-5 PMID: 38609535
pubmed: 38609535
doi: 10.1007/s10585-024-10283-5
pii: 10.1007/s10585-024-10283-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Mutch MG (2016) The Surgical Management of Colon Cancer. The ASCRS textbook of colon and rectal surgery. Springer, Berlin, pp 443–470
doi: 10.1007/978-3-319-25970-3_26
Vogel JD et al (2017) The American society of colon and rectal surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum 60(10):999–1017
pubmed: 28891842 doi: 10.1097/DCR.0000000000000926
Meyers BM et al (2016) Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol 23(6):418–424
pubmed: 28050138 pmcid: 5176375 doi: 10.3747/co.23.3330
Hu T et al (2016) Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol 22(30):6876–6889
pubmed: 27570424 pmcid: 4974586 doi: 10.3748/wjg.v22.i30.6876
Pan ST et al (2016) Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 43(8):723–737
pubmed: 27097837 doi: 10.1111/1440-1681.12581
Recasens A, Munoz L (2019) Targeting cancer cell dormancy. Trends Pharmacol Sci 40(2):128–141
pubmed: 30612715 doi: 10.1016/j.tips.2018.12.004
Wang X, Zhang H, Chen X (2019) Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2:141–160
pubmed: 34322663 pmcid: 8315569
Maji S et al (2018) Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Advances in cancer research. Elsevier, Amsterdam, pp 37–75
Huang Z et al (2016) Stress management by autophagy: implications for chemoresistance. Int J Cancer 139(1):23–32
pubmed: 26757106 doi: 10.1002/ijc.29990
Oh JH, Deasy JO (2016) A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer. Brief Bioinform 17(3):468–478
pubmed: 26220932 doi: 10.1093/bib/bbv053
Talukdar S et al (2019) Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Elsevier, Amsterdam, pp 43–84
doi: 10.1016/bs.acr.2018.12.002
Gimenez-Bonafe P, Tortosa A, Perez-Tomas R (2009) Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9(3):320–340
pubmed: 19442052 doi: 10.2174/156800909788166600
Longley DB, Johnston PG (2005)  Molecular mechanisms of drug resistance. J Pathol 205(2):275–292
pubmed: 15641020 doi: 10.1002/path.1706
Fujita K et al (2017) Cancer therapy due to apoptosis: galectin-9. Int J Mol Sci 18:1
doi: 10.3390/ijms18010074
Keese M et al (2010) Fluorescence lifetime imaging microscopy of chemotherapy-induced apoptosis resistance in a syngenic mouse tumor model. Int J Cancer 126(1):104–113
pubmed: 19588498 doi: 10.1002/ijc.24730
Crea F et al (2015) The epigenetic/noncoding origin of tumor dormancy. Trends Mol Med 21(4):206–211
pubmed: 25771096 doi: 10.1016/j.molmed.2015.02.005
Lin W-J, Hsueh H-M, Chen JJ (2010) Power and sample size estimation in microarray studies. BMC Bioinform 11(1):1–9
doi: 10.1186/1471-2105-11-S3-S1
Tibshirani R (2006) A simple method for assessing sample sizes in microarray experiments. BMC Bioinform 7:1–6
doi: 10.1186/1471-2105-7-106
Linde N, Fluegen G, Aguirre-Ghiso J (2016) The relationship between dormant cancer cells and their microenvironment. Elsevier, Amsterdam, pp 45–71
Wajant H (2002) The Fas signaling pathway: more than a paradigm. Science 296(5573):1635–1636
pubmed: 12040174 doi: 10.1126/science.1071553
Kischkel FC et al (1995) Cytotoxicity-dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. EMBO J 14(22):5579–5588
pubmed: 8521815 pmcid: 394672 doi: 10.1002/j.1460-2075.1995.tb00245.x
Li H et al (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491–501
pubmed: 9727492 doi: 10.1016/S0092-8674(00)81590-1
Reed JC (2000) Mechanisms of apoptosis. Am J Pathol 157(5):1415–1430
pubmed: 11073801 pmcid: 1885741 doi: 10.1016/S0002-9440(10)64779-7
Stegh AH et al (1998) DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J 17(20):5974–5986
pubmed: 9774341 pmcid: 1170924 doi: 10.1093/emboj/17.20.5974
Gozuacik D, Kimchi A (2006) DAPk protein family and cancer. Autophagy 2(2):74–79
pubmed: 17139808 doi: 10.4161/auto.2.2.2459
Liang C (2010) Negative regulation of autophagy. Cell Death Differ 17(12):1807–1815
pubmed: 20865012 doi: 10.1038/cdd.2010.115
Levy-Strumpf N, Kimchi A (1998) Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 17(25):3331–3340
pubmed: 9916995 doi: 10.1038/sj.onc.1202588
Lamkanfi M, Kanneganti T-D (2010) Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol 42(1):21–24
pubmed: 19782763 doi: 10.1016/j.biocel.2009.09.013
Zheng H et al (2013) Fas signaling promotes motility and metastasis through epithelial–mesenchymal transition in gastrointestinal cancer. Oncogene 32(9):1183–1192
pubmed: 22508480 doi: 10.1038/onc.2012.126
Zheng H et al (2014) Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget 5(21):10763
pubmed: 25333257 pmcid: 4279408 doi: 10.18632/oncotarget.2498
Yuan J et al (2020) The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol 13(1):1–19
doi: 10.1186/s13045-020-00949-4
Xie Y et al (2019) PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia. Mol Med Rep 19(2):783–791
pubmed: 30535469
Hers I, Vincent EE, Tavaré JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515–1527
pubmed: 21620960 doi: 10.1016/j.cellsig.2011.05.004
Steelman LS et al (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12(9):1139–1165
pubmed: 18694380 doi: 10.1517/14728222.12.9.1139
Yang J et al (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):1–28
pubmed: 30609930 pmcid: 6320601 doi: 10.1186/s12943-019-0954-x
McCubrey JA et al (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46(1):249–279
pubmed: 16854453 doi: 10.1016/j.advenzreg.2006.01.004
Castel P et al (2021) The present and future of PI3K inhibitors for cancer therapy. Nat cancer 2(6):587–597
pubmed: 35118422 pmcid: 8809509 doi: 10.1038/s43018-021-00218-4
Gao X-l et al (2017) Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis. Onco Targets Ther 10:5219
pubmed: 29138574 pmcid: 5667781 doi: 10.2147/OTT.S140854
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Investig 119(6):1420–1428
pubmed: 19487818 pmcid: 2689101 doi: 10.1172/JCI39104
Veschi V et al (2020) Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene 39(5):987–1003
pubmed: 31591478 doi: 10.1038/s41388-019-1047-4
Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7(12):3670–3684
pubmed: 19074844 pmcid: 2637411 doi: 10.1158/1535-7163.MCT-08-0715
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes cancer 2(12):1097–1105
pubmed: 22866201 pmcid: 3411125 doi: 10.1177/1947601911423031
Gerhardt H et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161(6):1163–1177
pubmed: 12810700 pmcid: 2172999 doi: 10.1083/jcb.200302047
Cong R et al (2006) Hhex is a direct repressor of endothelial cell-specific molecule 1 (ESM-1). Biochem Biophys Res Commun 346(2):535–545
pubmed: 16764824 doi: 10.1016/j.bbrc.2006.05.153
Kang YH et al (2012) ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal 24(10):1940–1949
pubmed: 22735811 doi: 10.1016/j.cellsig.2012.06.004
Kolev V et al (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10(8):902–911
pubmed: 18604200 pmcid: 2747621 doi: 10.1038/ncb1750
Limbourg FP et al (2005) Essential role of endothelial Notch1 in angiogenesis. Circulation 111(14):1826–1832
pubmed: 15809373 pmcid: 2633594 doi: 10.1161/01.CIR.0000160870.93058.DD
Liu Z-J et al (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23(1):14–25
pubmed: 12482957 pmcid: 140667 doi: 10.1128/MCB.23.1.14-25.2003
Altobelli E et al (2015) HtrA1: its future potential as a novel biomarker for cancer. Oncol Rep 34(2):555–566
pubmed: 26035313 pmcid: 4487665 doi: 10.3892/or.2015.4016
Baldi A et al (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21(43):6684–6688
pubmed: 12242667 doi: 10.1038/sj.onc.1205911
Baldi A et al (2008) The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Future Med. https://doi.org/10.2217/14622416.9.8.1069
doi: 10.2217/14622416.9.8.1069
Zhu F et al (2010) Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 9(5):508–512
pubmed: 20943460
Lehner A et al (2013) Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One 8(4):e60359
pubmed: 23580433 pmcid: 3620283 doi: 10.1371/journal.pone.0060359
Catalano V et al (2011) HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 58(5):669–678
pubmed: 21447133 doi: 10.1111/j.1365-2559.2011.03818.x

Auteurs

Vugar Yagublu (V)

Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. vugar.yagublu@umm.de.

Bayram Bayramov (B)

Laboratory of Human Genetics, Genetic Resources Institute of Ministry of Science and Education, Baku, Azerbaijan.
Department of Natural Sciences, Western Caspian University, AZ1001, Baku, Azerbaijan.

Christoph Reissfelder (C)

Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Medical Faculty Mannheim, DKFZ-Hector Cancer Institute, Heidelberg University, Mannheim, Germany.

Javahir Hajibabazade (J)

Carver College of Medicine, University of Iowa, Bowen Science Building, 51 Newton Road, Iowa City, IA, 52242-1009, USA.

Shalala Abdulrahimli (S)

Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Laboratory of Human Genetics, Genetic Resources Institute of Ministry of Science and Education, Baku, Azerbaijan.

Michael Keese (M)

Department of Vascular Surgery, Theresienkrankenhaus and St. Hedwigsklinik, Mannheim, Germany.

Classifications MeSH